Zolbetuximab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and HAS (France), among others, recommended or restricted zolbetuximab, while AOTMIT (Poland), CIPM (Spain) and NICE (England), among others, did not recommend it.
The record spans 2.1 years, opening at CHUIKYO (Japan) on 15 May 2024 and running to 4 Jun 2026.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 15 of 15 records date from 2023 or later.
4 distinct indication wordings are recorded for zolbetuximab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CHUIKYO (Japan) was first to assess zolbetuximab, on 15 May 2024; HIRA (South Korea) did not open a file until 4 Jun 2026 — a moderate spread of 2.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 10 of 15 dated records fall in 2025 alone.
3 of the 12 agencies here assessed zolbetuximab more than once, CIPM (Spain) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
zolbetuximab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for zolbetuximab reads 7 recommended, 5 not recommended, 1 deferred to NICE and 1 deferred, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 28 Jan 2026 | Indicaciones terapéuticas autorizadas: Vyloy, en combinación con quimioterapia basada en platino y fluoropirimidina, est… | not financed by the SNS · art. 92 d | source |
| SMC (Scotland) | 19 Jan 2026 | In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastati… | accepted | source |
| AOTMIT (Poland) | 2 Jan 2026 | programu lekowego B.58. „Leczenie chorych na raka przełyku, połączenia żołądkowo-przełykowego i żołądka (ICD-10: C15-C16… | not recommended | source |
| DMC (Denmark) | 17 Dec 2025 | 1. linjebehandling af lokalavanceret, ikke-resektabel eller metastatisk HER2-negativ, Claudin 18.2-positiv adenokarcinom… | Anbefalet | source |
| NYE METODER (Norway) | 21 Sep 2025 | Kombinasjon med fluoropyrimidin- og platinaholdig kjemoterapi til førstelinjebehandling av voksne pasienter med lokalava… | not introduced | source |
10 further decisions for zolbetuximab, across 8 agencies, are not shown here. They include the most recent record on file, 4 Jun 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 15 decisions for zolbetuximab from 12 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.